EN | UA
EN | UA

Help Support

Back

GnRH-antagonists as promising agents to treat endometriosis

GnRH-antagonists as promising agents to treat endometriosis GnRH-antagonists as promising agents to treat endometriosis
GnRH-antagonists as promising agents to treat endometriosis GnRH-antagonists as promising agents to treat endometriosis

What's new?

Due to the remarkable efficacy of GnRH-antagonists for the management of moderate to severe pain associated with endometriosis, the Elagolix got FDA approval.

A newly published study in the Journal of Expert Opinion on Biological Therapy highlights the recent developments in the setting of endometriosis management. In the latest investigations, it was found that some of the females experience partial or no reduction in pain or its recurrence after the discontinuation of treatments like combined hormonal contraceptives and progestins, which are currently present as the first-line treatments for endometriosis. This is why new medications or treatments are needed for endometriosis management.

The most promising results regarding endometriosis treatment were shown by the aromatase inhibitors (AIs) and gonadotropin-releasing hormone (GnRH) antagonists. One of the GnRH, Elagolix also got approval by the Food and Drug Administration (FDA) for operating endometriosis. Other medications were also recognized but the majority these have only been assessed in early clinical trials or pre-clinical studies. Additional extensive clinical research is needed to illustrate their efficacy, safety and pharmacological characteristics in a better way. 

Source:

Expert Opin Biol Ther.

Article:

A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.

Authors:

Fabio Barra et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: